Budapest, Hungary

Qualiclinic

Rheumatoid Arthritis

Arthritis

Autoimmune Diseases

Musculoskeletal Diseases

Joint Diseases

Collagen Diseases

Connective Tissue Diseases

Immune System Diseases

Rheumatic Diseases

Systemic Lupus Erythematosus

KPL-404

LY3471851

Peresolimab

Kiniksa Pharmaceuticals

Lilly

Nektar Therapeutics

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The main purpose of this study is to assess the safety and efficacy of peresolimab in adult participants with moderately-to-severely active rheumatoid arthritis.

A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Qualiclinic | Budapest, Hungary

Site insights

Work at this site?

Active trials

A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (RESOLUTION-1)

Trial sponsors